Clinical Professor
Senior Medical Oncologist – Breast Cancer Clinics and Research        
MD, FRCP(C), LRCP, MRCS(UK)
phone: 6045962440

Dr. Ragaz is a Medical Oncologist, Breast Cancer Specialist and Clinical Professor at the Faculty of Medicine’s School of Population and Public Health (SPPH), University of British Columbia, (UBC), Vancouver, B.C., Canada.

CLINICAL ACTIVITIES
From 2011 to 2012, Dr. Ragaz was the Medical Director of the Breast Cancer Risk Reduction and Prevention Clinic at the University of British Columbia Women’s Health Centre.

In 2008 Dr. Ragaz opened the Vancouver-based Oncology Counselling, Education and Prevention Clinic, dedicated to in-depth counselling of patients with established Cancer and for Breast Cancer Prevention. Problematic issues are frequently discussed with current local, national and international opinion leaders.

From 2003 to 2008, Dr. Ragaz was the Director of the Oncology Program, McGill University Health Centre, McGill University, Montreal, Quebec, Canada, where he helped to expand and modernize the MUHC Oncology activities.

During his 1977-2003 tenure at the British Columbia Cancer Agency [BCCA], Vancouver, BC, Dr. Ragaz subspecialized in Breast Cancer, developing multiple provincial, national and international Clinical Research Initiatives.

ACADEMIC RESEARCH & UNIVERSITY TEACHING
Dr. Ragaz is currently active at the School of Population and Public Health, University of British Columbia, working with the teams of local and international academic collaborators on a variety of Cancer Epidemiology and Outcome projects. [see CLINICAL RESEARCH ACTIVITIES – Summary, below ]

Along with his clinical and research activities, Dr. Ragaz also teaches a postgraduate course [SPPH 524] for the students of Masters and PhD Programs, at the UBC School of Population and Public Health.

PATIENT ADVOCACY.
2005–Present (July 2012): Board Member, Director, Cancer Advocacy Coalition of Canada [http://www.canceradvocacy.ca]. Dr. Ragaz is an active champion of patient’s rights to access the best cancer care, as seen from his many activities.

BACKGROUND
2012. Dr. Joseph Ragaz is a MEDICAL ONCOLOGIST – Breast Cancer Specialist, Clinical Professor, Faculty of Medicine, School of Population and Public Health (SPPH), University of British Columbia, Vancouver B.C., Canada; and Adjunct Clinical Professor, Medicine & Oncology, McGill University, Montreal, Quebec, Canada

2009 – present [2012]. Instructor of the UBC SPPH course 524

2009 – present [2012]: Director, Oncology Counselling, Research and Prevention Clinic, # 218, 809 West 41st ave, Vancouver, B.C., V5Z 2N6, Canada
Tel: 604-569-2440 Fax: 604-569-2446; e-mail1: joseph.ragaz@ubc.ca; e-mail 2: joseph.ragaz@mcgill.ca

2003 – 2008: Director, Oncology Program, McGill University Health Center, McGill University, Montreal, Quebec, Canada.

1977-2003: Senior Medical Oncologist and Breast Cancer Researcher at the British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada.

1973 – 1977: Medical Oncology Residency, Princess Margaret Hospital, Univeristy of Toronto, Toronto, Canada

1970 – 1973: Residency, Internal Medicine, Montreal General Hospital, McGill University, Montreal, Quebec, Canada

1968 – 1970: Westminster Medical School, University of London, London, UK

CLINICAL RESEARCH ACTIVITIES – SUMMARY:
2006 – 2012 [present] Cancer Outcome Projects – CANADA.
Cancer Epidemiology projects assessing Long-term Breast Cancer Incidence & Mortality trends in the Provinces of Canada, to correlate the outcomes with the organization of cancer care (collaboration: Public Health Agency of Canada, Canadian Cancer Registry and Statistics Canada).

2008 – 2012 [present]. Cancer Outcome Projects – CHINA.
Comparative analyses of Breast Cancer Incidence and Mortality trends between urban and rural China (Collaboration: Cancer Registries in Shanghai & Qidong & International Agency for Research on Cancer [IARC], Lyon, France).

2009 – 2012 [present]: Molecular classification of breast cancer tumors.
Cost–benefit analyses and the overall impact of a new guideline proposal where chemotherapy would be restricted to breast cancer patients without documented chemotherapy resistance [as determined on molecular classification of the tumor sample at diagnosis].

2009 – 2012. Breast Cancer Prevention.
Analyses of key Breast Cancer Prevention Initiatives and logistics of their implementation in British Columbia and Canada.

2000 – 2012. HRT reviews.
Since the 1990’s, Dr. Ragaz and his team have been monitoring, and at times providing additional analyses of HRT data to clarify the strengths and shortcomings of existing trials and identify issues responsible for the lack of clarity of the HRT data. (SABCS presentation 2010 (PDF) )

2006 – 2012. Impact of Cox2 and Aromatase Inhibition in Breast Cancer treatment and Cancer Prevention.

1997 – 2005. Post-Mastectomy Radiation therapy.
This seminal British Columbia randomized trial coordinated by Dr. Ragaz and his team (1997 New England Journal of Medicine & 2005 update, Journal of National Cancer Institute) helped to change in the late 1990s, along with a similarly designed Danish trial, the post-mastectomy radiation therapy guidelines for stage I-II breast cancer.

2000 – 2004. First phase, BCCA Molecular Biology project of Tissue Microarrays.
Start and completion of the first phase of the BCCA Tissue Microarray project, in collaboration with the UBC Pathology Group [GPEC] and several groups of international collaborators [Drs. M. Lippman, G. Sledge, K.Miller, S.Badwe, A.Brodie, A.Harris, etc.]. This project correlated, in 930 patients participating in British Columbia Breast cancer trials, the 20 year survival outcome according to the expression of novel molecular markers: Her2/Neu, VEGF, Cox2, uPA, Aromatase, EMSY, etc.

1990 – 2000. Breast Cancer Outcome unit.
In the late 1980s, Dr. Ragaz and his team conceptualized and obtained funding for the British Columbia Breast Cancer Outcome Unit – soon afterwards becoming one of the largest and most active Clinical Breast Cancer Outcome units in North America.

1977-1985. Neoadjuvant Therapy Program for early Breast cancer was piloted by Dr. Ragaz’ team in British Columbia in the late 1970’s, and eventually led to the guideline-acceptance of Neo-Adjuvant therapy for Breast Cancer in North America and Europe. Present updates identify Neoadjuvant setting as an ideal one to test new agents for cancer efficacy, substantially reducing the time required in testing & activating new agents into guidelines. [Ragaz, J.: Randomized Trials in Oncology: a necessity or time-consuming luxury. Breast Cancer Res. 2010]

1978 – 1980. Aromatase Inhibitors with Medical Adrenalectomy (Aminoglutethimide) in British Columbia and Canada.
One of the first international projects of Aromatase Inhibitors for breast cancer therapy.

Courses
SPPH 524

SELECTED PUBLICATIONS, Organization of cancer care: Molecular Classification and Clinical Trials

J. Ragaz, K.S. Wilson, H. Wong, G.Muraca, W. Hryniuk, C.Bajdik: Molecular classification with 21 gene assay: Definition of chemo resistance based on LRS with cost and guideline implications. Cancer Research, 2011, Vol .71; 135s

Ragaz J. : The 21 gene assay: Impact on breast cancer in Canada. Ethically and economically when do we act? Cancer Advocacy coalition of Canada, March 2010, the 2009-2010 Report Card.

Ragaz J: Randomized adjuvant trials in Oncology: A necessity or time-consuming luxury? Breast Cancer Research 2010, 12(Suppl 4):S14. (in press)

SELECTED PUBLICATIONS, Cancer Epidemiology: Breast Cancer Incidence and Mortality Trends, Canada & China

Ragaz J, Spinelli JJ, Semeniciw R, Hryniuk W, Budlovsky J, Franco E.: Breast cancer mortality reduction in the western world: therapeutic versus diagnostic interventions. Implications for cancer care organization processes. Cancer Research, Vol 69; Supl; January 2009; p383s # 6083.

J.Ragaz, H. Wong, H.Qian: Comparative analysis of Breast Cancer (BrCA) mortality reduction among Regions of Canada between 1950 – 2004: Impact of systemic and diagnostic guidelines after 1977, with Model definition of potentially avoided Annual deaths. Cancer Research 2009, Vol. 69, pp 613s.

J.Ragaz, P.Bao, P Pisani, Y. Zheng Breast Cancer Mortality Trends in the WEST compared to the EAST: Lives gained, Lives lost. Cancer Research, Vol 69; January 2009; p383s

J. Ragaz, J.G. Chen, P. Bao, X. Hu , Y. Zheng, H. Wong, H. Qian: Rapid Increase in Breast Cancer (BrCa) with Regional Mortality Differences in China: Adverse effects of the Westernization and benefits of the Western interventions. JCO, 2009, Suppl., ASCO, Breast, Sept. 2009.

J.Ragaz, JJ Spinelli, G.Villeneuve, L. Ellison, A. Coldman: Mortality reduction of breast cancer in Canada: Impact of cancer care infrastructure. JCO, 2005, Vol. 23; (No. 16S): p40.

SELECTED PUBLICATIONS, Hormone Replacement Therapy (HRT).

Ragaz J., Shakeraneh S: Estrogen Prevention of Breast Cancer: A Critical Review. In: Estrogen Prevention of Breast Cancer; S. Suba [ed]., Nova Science, New York, 2012, in press.

Ragaz J, Budlovsky Joshua: Hormone Replacement Therapy: A critical Review. In: Manual of Breast Disease; I Jatoi, E.Kaufmann (eds.), Springer-Verlag, New York 2010, pp 451 – 473.

Ragaz J, J.Budlovsky, J.J. Spinelli, N.Le: Protective effect of Estrogen (E2) alone and increased risk of E2 plus Progestins on Brast Cancer. The 2009 review of the Women’s Health Initiative HRT Published trials. Cancer Research, 2009, Vol. 69, N 24, pp 533s.

Ragaz J: Hormone replacement therapy in patients with a prior breast cancer history: A critical review. In: Manual of Breast Disease. (ed) Ismail Jatoi. Lippincott Williams & Wilkins, 2002, 389-415.

Ragaz J, Coldman A. Age-matched all cause-mortality impact of hormone replacement therapy (HRT): Applicability to breast cancer survivors. Breast Ca Res Treat 57-58 A23, 1999.

SELECTED PUBLICATIONS, Prevention of human Breast Cancer: Possible?

Ragaz J.: Cancer Prevention in Canada: The Sooner the Better. The Report Card, Cancer Advocacy Coalition, Canada, 2011.

Ragaz, J., Spinelli, J.J.; Coldman, A; Mihalciou, C: Is Tamoxifen prevention of Breast Cancer (BrCa) underutilized in younger women? Analysis of competing cause mortality. Journal Clin Oncol, Suppl., 2006; Vol. 24; p 39.

Ragaz J., Coldman A. : Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. Journal of Clinical Oncology. 16(6):2018-24, 1998.

Ragaz J. : Interaction of tamoxifen’s impact on overall net mortality and quality of life. Oncology. 1(2 Suppl 1):45-8, 1997 Feb.

SELECTED PUBLICATIONS, Radiotherapy in Early Breast Cancer

Ragaz J: Radiation impact in breast cancer. Breast Cancer Res. 2009;11 Suppl 3:S14. Epub 2009 Dec 18. Review, pp 1-5.

Ragaz J. Olivotto IA. Spinelli JJ. et.al.: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute (the JNCI). 97(2):116-26, 2005 Jan 19.

Ragaz J. Jackson SM. Le N. Plenderleith IH. Spinelli JJ. et al.: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.[see comment]. [Clinical Trial. Journal Article. Randomized Controlled Trial] New England Journal of Medicine. 337(14):956-62, 1997 Oct 2. UI: 9309100

Ragaz J. Spinelli JJ. Coldman AJ. Breast cancer survival advantage with radiotherapy. Lancet. 356(9237):1270-71, 2000 Oct 7. UI: 11072966

Ragaz J. Spinelli JJ. Wide-field radiation as adjunct to adjuvant chemotherapy in high-risk cases with early breast cancer: do it or not?[comment].[Journal Article] International Journal of Cancer. 87(3):423-6, 2000.

Ragaz J. Jackson SM. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer 2000. 89(1):223-5.

Ragaz J. Spinelli JJ. Large breast cancer tumors and radiotherapy: biology vs. chronology.[comment]. [Comment. Editorial] Radiotherapy & Oncology. 1999; 52(3):203-5.

SELECTED PUBLICATIONS, Molecular Biology aspects of Breast Cancer: the First British Columbia Tissue Miocroarray Project.

Callagy GM., Pharoah PD., Pinder SE., Hsu FD., Nielsen TO., Ragaz J., Ellis IO., Huntsman D., Caldas C.: Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clinical Cancer Research. 12(8):2468-75, 2006 Apr 15. UI: 16638854

Nielsen TO., Hsu FD., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen LA., Ragaz J., Gown AM., Gilks CB., van de Rijn M. ,Perou CM. : Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research. 10(16):5367-74, 2004 Aug 15. UI: 15328174

Hughes-Davies L., Huntsman D., Ruas M., Fuks F., Bye J., Chin SF., Milner J., Brown LA., Hsu F., Gilks B., Nielsen T., Schulzer M., Chia S., Ragaz J. et.al. : EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.[see comment]. Cell. 115(5):523-35, 2003 Nov 26. UI: 14651845

Nielsen TO., Andrews HN., Cheang M., Kucab JE.,Hsu FD., Ragaz J. et.al. : Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor surviva. Cancer Research. 64(1):286-91, 2004 Jan 1. UI: 14729636

Ragaz J., Miller K., Badve S., Dayachko Y., Dunn S., Nielsen T., Brodie A., Huntsman D., Bajdik C., Sledge G. : Adverse association of expressed vascular endothelial growth factor (VEGF), Her-2, Cox-2, uPA and EMSY with long-term outcome of Stage I-III breast cancer (BrCA). J Clin Oncology; Suppl. 2004 July 15; Vol. 22 p. 14S.

J.Ragaz, C.Bajdik, J.J. Spinelli, M.Hayes, D. Jelacic, A.Brodie. Significant expression of Cox-2 according to Aromatase. Long-term follow up of the British Columbia Tissue Microarray project. Breast Ca Res Treat 2004; Vol.88; #109; S22.

SELECTED PUBLICATIONS, Molecular Biology aspects of Breast Cancer: Herceptin & Cancer Kinetics

Zhao X., Xu X., Guo L., Ragaz J., Guo H., Wu J., et al. : Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat. 2010 Sep 30. (Epub ahead of print) PMID: 20882405 [PubMed].

Ragaz J., Spinelli J.J : Cost-benefit estimates of Adjuvant (Adj) Trastuzumab (Herceptin, H) for early Breast Cancer (BrCa). Breast Ca Res & Treat 2005; 94: S 93.

Ragaz J.: Impact of HER-2/neu expression on natural history and outcome of human breast cancer. In: Breast diseases, J Harris, M Morrow, M Lippman, K Osborne, eds., Lippincott Williams and Wilkins, June 2004.

Ragaz J., Simpson-Herren L., Lippman M., Fisher B. : Questions related to the effects of therapy on biology and kinetics of the surviving tumor. [Journal Article] Progress in Clinical & Biological Research. 354A:1-6, 1990. UI: 2247483

Ragaz J: Biologic aspects, classification, surgery, and radiotherapy of stage III breast cancer. [Review] [38 refs] [Clinical Trial. Journal Article. Review] Current Opinion in Oncology. 2(6):1053-67, 1990 Dec. UI: 2099837

SELECTED PUBLICATIONS, Neoadjuvant Therapy of Breast Cancer

Ragaz J. Goldie JH. Baird R. Rebbeck P. Basco V. Coldman A. Experimental basis and clinical reality of preoperative (neoadjuvant) chemotherapy in breast cancer. [Journal Article] Recent Results in Cancer Research. 115:28-35, 1989.

Ragaz J. Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia Trial. [Clinical Trial. Comparative Study. Journal Article] Recent Results in Cancer Research. 103:85-94, 1986.

Ragaz J. Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy. [Clinical Trial. Journal Article. Randomized Controlled Trial] NCI Monographs. (1):145-52, 1986.

Ragaz J. Baird R. Rebbeck P. Goldie J. Coldman A. Spinelli J. Neoadjuvant (preoperative) chemotherapy for breast cancer. [Journal Article] Cancer. 56(4):719-24, 1985 Aug 15.

SELECTED PUBLICATIONS, Oxford Overview Meta-analyses of Early Breast Cancer, 1985 – 2005

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet; Volume 366, Issue 9503, 17 December 2005-6 January 2006, Pages 2087-2106.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet; 09/19/1998, Vol. 352 Issue 9132, p930-942

SELECTED PUBLICATIONS, Breast Cancer outcomes: The BCCA Breast Cancer Outcome Unit

Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA: Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat. 2010 Sep;123(2):597-605.

Truong PT. Woodward WA. Thames HD. Ragaz J. et.al.: The ratio of positive to excised nodes identifies high-risk subsets. [Comparative Study. Journal Article. Multicenter Study. Randomized Controlled Trial] International Journal of Radiation Oncology, Biology, Physics. 68(1):59-65, 2007 May 1.

Chua B. Olivotto IA. Weir L. Kwan W. Truong P. Ragaz J. Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia. [Journal Article. Research Support, Non-U.S. Gov’t] Breast Journal. 10(1):38-44, 2004 Jan-Feb.

Bryce C. , Kennecke H., Chia S., Ragaz J. Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer. Journal of Clinical Oncology. 21(23):4465- 66, 2003 Dec 1.

Olivotto IA. Chua B. Allan SJ. Speers CH. Chia S. Ragaz J. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. [Journal Article] Journal of Clinical Oncology. 21(5):851-4, 2003.

SELECTED PUBLICATIONS, Aromatase inhibitors in Breast Cancer.

Ragaz J. Status of aromatase inhibitors in relation to other breast cancer treatment modalities. [Review] [145 refs] [Journal Article. Review] Endocrine-Related Cancer. 6(2):277-91, 1999 Jun.

Ragaz J. Buskard N. Manji M. Thrombocytopenia after combination therapy with aminoglutethimide and tamoxifen: which drug is to blame?. [Case Reports. Journal Article] Cancer Treatment Reports. 68(7-8):1015-6, 1984 Jul-Aug.

BOOKS

1. Ragaz J, Simpson-Herren L, Lippman M, Fisher B eds. Effects of Therapy on the Biology and Kinetics of the Surviving Cancer. Preclinical, Basic Research – Part A. Willey-Liss, New York, 1990.

2. Ragaz J, Simpson-Herren L, Lippman M, Fisher B eds. Effects of Therapy on the Biology and Kinetics of the Surviving Cancer. Clinical – Part B. Willey-Liss, New York, 19901. Ragaz J, Ariel I, eds: High Risk Breast Cancer – Diagnosis. Springer-Verlag, Heidelberg, 1989.

3. Ragaz J, Ariel I, ed. High Risk Breast Cancer – Therapy. Springer-Verlag, Heidelberg, 1991.

4. Ragaz J, Band P, Goldie JH, eds. Preoperative (Neoadjuvant) Therapy of Cancer. Springer-Verlag, Heidelberg, 1986.

CHAPTERS

1. Ragaz J, Budlovsky J.: Hormone Replacement Therapy: A critical Review. In: Manual of Breast Disease; I Jatoi, E.Kaufmann (eds.), Springer-Verlag, New York 2010, pp 451 – 473.

2. Ragaz J: Impact of HER-2/neu expression on natural history and outcome of human breast cancer. Breast diseases, J Harris, M Morrow, M Lippman, K Osborne, eds., Lippincott Williams and Wilkins, June 2004.

3. Ragaz J, Spinelli JJ: Survival impact of locoregional radiation in Stage I-II breast cancer: Evidence-based review. In: Breast Cancer Management: Application of clinical and translational evidence to patient care. Second edition; JM Nabholtz, K Tonkin, D Reese, M Apro, A Buzdar eds., WW Lippincott, New York, 2002.

4. Ragaz J, Jackson S: Survival gains of locoregional radiation in early breast cancer. (eds) Nabhotz M, Tonkin K, Aapro MS, Buzdar AU. Martin Dunitz 2000; 285.
Ragaz J, Coldman A, Salinas F, Worth A, Manji M, Goldie JH: Preoperative Chemotherapy of Cancer. In Breast Cancer, I. Ariel, B. Cleary eds., McGraw Hill, New York; 312-328; 1986.

5. Ragaz J: Hormone replacement therapy in patients with a prior breast cancer history: A critical review. In: Manual of Breast Disease. (ed) Ismail Jatoi. Lippincott Williams & Wilkins, 2002, 389-415.

6. Ragaz J, Ariel IM: Future and Developmental Aspects of High Risk Breast Cancer Therapy. In: High Risk Breast Cancer, J. Ragaz, IM Ariel (eds), Springer-Verlag, New York, Heidelberg, 493-511, 1991.

7. Ragaz J: Role of Preoperative Therapy in High Risk Breast Cancer: Review. In: High Risk Breast Cancer. J. Ragaz, IM Ariel (eds), Springer-Verlag, New York, Heidelberg, 71-85, 1991.

8. Ragaz J, Ariel IM: Therapeutic Highlights of High Risk Breast Cancer: Comments Related to Surgery, to Radiotherapy and Hormone Therapy. In: High Risk Breast Cancer – Therapy, J. Ragaz, IM Ariel (eds), Springer-Verlag, New York Heidelberg 2-25, 1991.

9. Ragaz J: Review of the Effects of Therapy and Biology in Kinetics of Surviving Tumor Part I. In: Effects of Therapy on Biology and Kinetics of the Residual tumor Part A: Preclinical Aspects, J. Ragaz, L. Simpson-Herren, ME Lippman, B. Fisher (eds), Wiley-Liss, 7-21; 1990.

10. Ragaz J: Comments on kinetics and biology of the residual cancer and on relevant therapeutic strategies based on these phenomena. Part I and II. In: Progress in Clinical and Biological Research, Wiley-Liss, New York, Volume 354 A and B: 117-141, 19

11. Ragaz J: Comments on future developments of cancer therapy taking into consideration tumor biology and kinetics. Part I and II. In: Progress in Clinical and Biological Research, Wiley-Liss, New York, volume 354 A and B: 379-387, 1990.

12.Ragaz J, Ariel IM: High risk breast cancer: Definition of the risk. In: High Risk Breast Cancer. J. Ragaz, IM Ariel (eds), Springer-Verlag (Heidelberg), 3-25; 1989.

13. Ragaz J, Goldie JH, Baird R, et al: Experimental Basis and Clinical Reality of Preoperative (Neoadjuvant) Chemotherapy in Breast Cancer. In: Recent Results in Cancer Research, Springer-Verlag (Heidelberg), 115: 28-351; 1989.

14. Ragaz J, Manji M, Olivotto I, Knowling M, Basco V, Plenderleith I. Preoperative Combined Modality (Neoadjuvant) Therapy of Locally Advanced Breast Cancer. In Fundamental Problems in Breast Cancer. Patterson AHG, Lee A, eds., Martinus Nijhof, 1987, 383-391.

15. Ragaz J: Management of Stage III Breast Cancer: New Developments. In Endocrine Related Breast Cancer, B. Stoll Ed.; 1986.

16. Rootman J, Ragaz J, Cline R, Lapointe J: Metastatic and Secondary Tumors of the Orbit. In J. Rootman Ed.: Diseases of the Orbit 1987.